Bristol-Myers Squibb Co. (BMY)

50.57
NYSE : Health Technology
Prev Close 50.07
Day Low/High 49.99 / 50.85
52 Wk Low/High 42.48 / 63.69
Avg Volume 12.47M
Exchange NYSE
Shares Outstanding 1.64B
Market Cap 81.90B
EPS 3.00
P/E Ratio 13.09
Div & Yield 1.64 (3.27%)
Cramer: I'll Give You the Key to the Rally

Cramer: I'll Give You the Key to the Rally

You have to keep up with the sector rotations.

Takeaways and Observations

"Bull markets are born on pessimism, grow on skepticism, mature on optimism and die on euphoria." -- Sir John Templeton  DuPont (still on my Best Ideas List) and 3M accounted for 110% of today's gain in the Dow Jones Industrial Average.  It was the ...

Cramer: Is the Market Playing 'The Price Is Wrong'?

Cramer: Is the Market Playing 'The Price Is Wrong'?

These may be uncharted waters, but they're not necessarily expensive.

Cramer: Buyers for Bristol-Myers Are Few and Far Between

Cramer: Buyers for Bristol-Myers Are Few and Far Between

Icahn may have a tough time finding interest in this behemoth.

Jim Cramer Talks Tesla, TJX, Square, Fitbit and National Margarita Day!

Jim Cramer Talks Tesla, TJX, Square, Fitbit and National Margarita Day!

TheStreet's Jim Cramer comments on Wednesday's most talked about stocks.

Wake Up Wall Street: Dow Jones Secures Eighth Straight Day of Gains

Wake Up Wall Street: Dow Jones Secures Eighth Straight Day of Gains

Here are 5 things you must know before the market opens Wednesday.

Toll Brothers Beats Expectations, Icahn Buys Stake in Drug Maker

Toll Brothers Beats Expectations, Icahn Buys Stake in Drug Maker

Toll Brothers TOL says the average price of a home it built declined, due to the cost of building materials.

Takeaways and Observations

  Every single market indicator I look at is overbought.  But it's likely that shorts and underperformers are buoying stocks.  Some are at the most overbought in decades.  The bond market is clearly not as sanguine on economic growth/corporate profi...

Activist Investors Shake Up the Boards at Tiffany & Bristol-Myers Squibb

Activist Investors Shake Up the Boards at Tiffany & Bristol-Myers Squibb

Jana Partners are placing three members on Tiffany's board.

Your Burning Biotech Questions Answered

Your Burning Biotech Questions Answered

We explore whether the biotech rally can continue and if Gilead Sciences has bottomed.

Your Burning Biotech Questions Answered

Your Burning Biotech Questions Answered

We explore whether the biotech rally can continue and if Gilead Sciences has bottomed.

Health Care ETF Has Been Ailing

Health Care ETF Has Been Ailing

You might want to review your holdings in the sector.

Takeaways and Observations

I started the day with a discussion of the new administration's policies and why I believe there are headwinds to their passage over the next few months or quarters.  I covered last evening's Procter & Gamble short for a profit.  "For Traders Only."...

Biotech Buoyed by Deal Talk

Biotech Buoyed by Deal Talk

M&A activity is in a serious upswing, and here are some names to watch.

Cramer: Allergan Is the New Pharma Growth Stock

Cramer: Allergan Is the New Pharma Growth Stock

Jim Cramer compares Allergan's growth to other pharma stocks.

Cramer: Trump's Carrot-Stick Approach Doesn't Make Pharma Any More Attractive

Cramer: Trump's Carrot-Stick Approach Doesn't Make Pharma Any More Attractive

Two industries should largely be avoided under this administration: pharma and retail.

7 Things to Watch in Biotech Now

7 Things to Watch in Biotech Now

M&A, drug approvals and Trump are all on my watch list.

Bristol-Myers numbers cut at Jefferies

My Takeaways and Observations

"The Dow hit 20,000 and I am proud of it ... Now we have to go up, up, up. It's gone up a lot since I won. We hit a number that has never been hit before. So, I am very honored." --President Donald Trump, ABC interview Wednesday night If the market ...

Jim Cramer: Bristol-Myers Needs to Slim Down

Jim Cramer: Bristol-Myers Needs to Slim Down

Bristol-Myers Squibb needs to reorganize itself in what is now a challenging environment, says Jim Cramer.

Dow May Linger at 20K for a While

Dow May Linger at 20K for a While

I am reluctant to call this a breakout, and am willing to sit back and wait.

Bristol-Myers numbers cut at BMO

Synergy Pharmaceuticals Consolidating Recent Gains

The market continues to be in rally mode as everyone watches the presidential inauguration ceremonies. Biotech is not participating in the rally. Bristol Myers-Squibb is one reason the sector is not participating, as its key oncology drug Opdivo wil...

Jim Cramer Shares His Concerns About Bristol-Myers Squibb

Jim Cramer Shares His Concerns About Bristol-Myers Squibb

Jim Cramer looks at Bristol-Myers Squibb's Opdivo setback.

Setback for Bristol-Myers on Lung Cancer Treatment Drugs

Setback for Bristol-Myers on Lung Cancer Treatment Drugs

Bristol-Myers Squibb suffers a setback in immunotherapy treatment for newly diagnosed lung cancer.

My Takeaways and Observations (Early Edition)

I had my most active day of the year trading. It was also my most profitable.   Regardless of one's market view, I continue to see more opportunities on the trading side vs. the investing side in the months ahead.   I started the day with a story re...

Why Bristol-Myers Squibb May Be a Merger Target Soon

Why Bristol-Myers Squibb May Be a Merger Target Soon

Jana Partners' Barry Rosenstein recently acquired a large stake in Bristol-Myers.

Closing Bell: Volkswagen Secures Plea Deal; Trump Triggers Biotech Selloff

Closing Bell: Volkswagen Secures Plea Deal; Trump Triggers Biotech Selloff

Wall Street secured gains again by late afternoon Wednesday in unpredictable trading following President-elect Donald Trump's first press conference since July.

3 Takeover Candidates in the Drug Space

3 Takeover Candidates in the Drug Space

Potential acquirers include Gilead Sciences, Johnson & Johnson, Pfizer, Merck and Novartis.